Please provide your email address to receive an email when new articles are posted on . There were no new safety signals, and treatment-emergent adverse events were comparable in the AXS-05 group and ...
AXS-07, targeting chronic migraine, has shown promising results in Phase 3 trials but faced a CRL from the FDA due to CMC issues. The FDA has set a new PDUFA date for AXS-07 on January 31, 2025, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback